Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
FDA reporter Lizzy Lawrence joins 'The Readout LOUD' to dissect Dr. Makary's departure from his role, the policies that may endure, and the implicatio...
Xeber.world
drug approval
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Trump Administration Speeds Up FDA Commissioner Search After Makary Resignation
The Trump administration is accelerating efforts to appoint a new FDA commissioner following Marty Makary's resignation. The ideal candidate must rest...
Sanofi Withdraws Teplizumab from FDA Fast-Track Review Amid Leadership Dispute
Sanofi has requested the FDA remove its type 1 diabetes drug teplizumab from a fast-track review program after a dispute between agency staff and acti...
FDA Revisits Rare Cancer Drug Approval After Unexpected Rejection Sparks Controversy
The FDA is reconsidering its decision to reject a treatment for a rare cancer after an unexpected rejection. Meanwhile, experts question the Trump adm...
Sanofi Withdraws Teplizumab from FDA’s Fast-Track Review Program Amid Controversy Over Political Interference
Sanofi has requested the FDA remove its type 1 diabetes drug, teplizumab, from Commissioner Marty Makary’s expedited review program. The move follows...
Pfizer and BridgeBio Secure Patent Win: Key Biotech Developments Today
Italian pharma giant Chiesi acquires KalVista Therapeutics for $1.9 billion, adding a rare-disease treatment to its portfolio. Meanwhile, major biotec...
Sanofi's Multiple Sclerosis Drug Secures Positive EU Review After US Rejection
Sanofi’s multiple sclerosis drug received a positive review from European regulators, marking a stark contrast to its rejection by the FDA in late 202...
FDA Reversal on Peptide Ban Under RFK Jr. Sparks Safety Concerns, Say Former Officials
The FDA banned 19 peptide drugs for compounding pharmacies in 2023 due to safety concerns. Now, under HHS Secretary RFK Jr., the agency may reverse th...